A surprising backup pathway allows cells to make a crucial amino acid when their primary machinery fails.
For decades, biologists believed cells had only one way to access a molecule they cannot live without. New research suggests they were wrong.
Scientists at Montana State University have uncovered a previously unknown cellular survival pathway that allows mammalian cells to keep producing the essential amino acid cysteine even when the systems long thought to be indispensable are disabled. The discovery challenges a fundamental assumption in cell biology and could eventually point researchers toward new strategies for making cancer treatments more effective.
The findings were published in Nature Chemical Biology.
"All cells need a constant supply of an amino acid called cysteine in order to stay alive," said the paper's lead author Ed Schmidt, a professor of genetics and development in the Department of Microbiology and Cell Biology in MSU's College of Agriculture. "Yet cysteine is not available outside of the cells."
That creates a major problem for cells. Cysteine is required to build proteins, maintain their structure, and protect cells from damage caused by highly reactive molecules. Without a reliable supply, cells quickly lose the ability to carry out basic functions needed for survival.
Because cells cannot obtain cysteine directly from their environment, they normally generate it from an oxidized compound called cystine. This process relies on a mechanism known as a disulfide reductase system.
"Scientists long believed this process was absolutely essential for all living cells," Schmidt said. "However, we have discovered a previously unknown system in mammalian cells that can take over when the main systems fail."
An Unexpected Discovery
The breakthrough emerged over nine years and involved several key stages. According to Schmidt, the first clue appeared in 2014 when a group of mice survived despite lacking any known way to convert cystine into cysteine.
"This was supposed to be impossible," he said. "No living organism or cell had ever been found that could live without having a functioning disulfide reductase system."
The result was not accidental. Schmidt had previously engineered mouse models that each lacked one of the liver's two main disulfide reductases.
"Some of the physiological responses we were seeing in the livers of each of those mouse lines suggested to me that the belief that no cell could live without having at least one of these two reductases might not be correct," he said. "I wanted to test this."
Working with collaborator Peter Nagy of the Hungarian National Institute of Oncology in Budapest, Schmidt's team spent seven years determining how the animals continued producing cysteine without a functioning disulfide reductase system.
The researchers found that cells can switch to an alternative pathway when the standard system is unavailable. Instead of breaking a disulfide bond, this backup mechanism cuts a nearby carbon-sulfur bond within cystine, releasing cysteine that the cell can use.
Schmidt said the newly identified pathway may have evolved as a defense against electrophilic toxins. These toxic compounds are produced by some organisms to kill predators or other threats.
"The ability of our cells to survive, at least for a time, without disulfide reductases, likely evolved in our earliest multicellular ancestors as a mechanism that allowed these organisms to resist being killed by electrophilic toxins made by the things they ate or the things found in their environment," Schmidt said.
Implications for Cancer Research
The same survival mechanism may also help certain cancer cells withstand treatments such as chemotherapy, radiation therapy, and immunotherapy.
"This same pathway that protects our cells from oxidants or toxins also likely protects cancer cells from therapies," Schmidt said. "Now that we know they have this defense mechanism, we might be able to precisely disable it in cancers, making them more susceptible to cancer therapies, as well."
Several MSU students contributed to the study, including co-first authors Zoe Seaford and Sydney Austad, who conducted the work as undergraduate researchers in Schmidt's laboratory. Martina Serrano Alvarez and Reed Noyd also participated as undergraduates, while Colin Miller contributed as a doctoral student. Scientists and trainees from multiple institutions collaborated on different aspects of the research.
"This scientific breakthrough underscores the power of research to redefine what we thought was possible and advance new approaches to cancer treatment," said Sreekala Bajwa, dean of the College of Agriculture. "I congratulate Dr. Schmidt and his team for their exceptional achievement and for engaging students as true partners in research that delivers global impact."
Reference: "Cystine C–S bond cleavage fuels cysteine production under disulfide reductase deficiency" by Edward E. Schmidt, Eszter Petra Jurányi, Colin G. Miller, Sydney A. Austad, Tamás Ditrói, Zoe M. Seaford, Sang Jun Yoon, Reed C. Noyd, Yun Pyo Kang, Justin R. Prigge, Vivien Csikós, Martina Serrano Alvarez, Katalin Erdélyi, Dóra Kővári, Gina M. DeNicola and Peter Nagy, 21 May 2026, Nature Chemical Biology.
DOI: 10.1038/s41589-026-02213-1
News – Curated by Amanda Scott, Alias Group Creative
Follow her on Bluesky
Brazilian Tree Compounds Fight COVID-19 on Multiple Fronts
Scientists found compounds in a Brazilian tree that hit SARS-CoV-2 on multiple fronts, revealing a promising new lead in the search for COVID-19 treatments. Researchers have found that galloylquinic acids extracted from the leaves [...]
Cutting Two Amino Acids Slowed Prostate Cancer in Mice
A newly identified link between amino acid metabolism and cholesterol production may help prostate tumors adapt to hormone therapy. Prostate cancer can find ways around treatments designed to deprive tumors of the hormones they [...]
Largest-Ever Physics Survey Raises New Doubts About Our Model of the Universe
Physicists around the world remain deeply divided on key mysteries of the universe, from dark matter to quantum gravity. The standard cosmological model failed to gain majority support, and no leading theory dominated the [...]
Scientists Just Overturned a 100-Year-Old Belief About Bacteria in the Lungs
New findings raise questions about the role of microbes living in the lungs. More than 35 trillion bacteria live throughout the human body, forming microbiomes in the gut, mouth, lungs, skin, and urogenital tract. [...]
GHCE Concept
From the preface of the book Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artificial Intelligence, Edited by Frank Boehm: Since the publication of my first book (Nanomedical Device and Systems [...]
Novartis, Ionis drug failure spurs questions
Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a result with important implications for cardiovascular drug research. Dive Brief: An RNA drug from [...]
New injectable treatment helps the brain rebuild after stroke
Biomedical engineers at Duke University have created an injectable biomaterial that may help the brain recover from damage left behind by an ischemic stroke. In experiments with mice, the material transformed the cavity created [...]
Scientists Discover a Hidden “Immune Organ” Inside the Skull
Researchers discovered lymph node-like immune hubs inside skull bone marrow that appear to act as rapid-response centers for the brain. For decades, the brain was thought to operate largely apart from the immune system. [...]
Engineered tRNAs and lipid nanoparticles target nonsense mutation cystic fibrosis
Researchers have developed a potential new approach for treating a form of cystic fibrosis caused by so-called nonsense mutations, combining chemically modified transfer RNAs with lipid nanoparticles designed to deliver the therapy directly to [...]
New pancreatic cancer drug carries a $39,800 monthly list price
A groundbreaking treatment for one of the most common forms of pancreatic cancer has been approved in pill form by the FDA. Revolution Medicines’ oral tablet daraxonrasib, branded as Rasonque, reduced the risk of [...]
Researchers Have Discovered a New Way To Reduce Chronic Nerve Pain
A cancer-linked protein called BRAF may help drive chronic nerve pain, and existing cancer drugs targeting it reduced pain sensitivity in preclinical models. Chronic nerve pain can persist long after an injury and often [...]
Our books now available worldwide!
Online Sellers other than Amazon, Routledge, and IOPP Indigo Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artifcial Intelligence Global Health Care Equivalency In The Age Of Nanotechnology, Nanomedicine And Artificial [...]
Quantum-Enabled Regenerative Health: Reimagining Wellness, Precision Health and Longevity Medicine
Introduction Healthcare is approaching a frontier where the quantum portfolio could influence not only how disease is diagnosed and treated, but how health itself is measured, modeled, predicted and preserved. Quantum computing, quantum simulation, [...]
FDA Clears First-of-Its-Kind Nonmedication Treatment for PTSD
The FDA has cleared a system that uses brain activity data to personalize magnetic stimulation for PTSD, adding a new nonmedication treatment option. Every day in the United States, approximately 17.5 veterans die by suicide, [...]
FDA approves breakthrough drug to treat advanced pancreatic cancer
The Food and Drug Administration (FDA) approved on Wednesday a drug that could extend the survival of those with metastatic pancreatic cancer. The drug, called daraxonrasib, will be sold under the brand name Rasonque [...]
AI Decodes a Hidden DNA Signal Linked to Disease-Causing Mutations
Machine learning identifies the likely “initiator” and enables new predictions about DNA mutations that can cause disease. Every human cell depends on tens of thousands of genes being switched on at the right time [...]















